ArticleRadiological physics and technology2026
Evaluation of a Monte Carlo-based independent dose calculation system for brain stereotactic radiotherapy using a robotic radiosurgery system.
Article in Radiological physics and technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the dose calculation accuracy of a Monte Carlo (MC)-based independent dose calculation system (IDCS) for CyberKnife brain stereotactic treatment plans and compared it with ray-tracing (RT) and MC algorithms within the MultiPlan treatment planning system (TPS). Beam modeling accuracy was validated for 11 circular fields using measured output factors (OPF), percentage depth dose (PDD), and off-center ratio (OCR). A total of 200 retrospective brain stereotactic treatment plans were analyzed (50 prescribed 23 Gy in 1 fraction, 50 prescribed 35 Gy in 3 fractions, and 100 prescribed 41.5 Gy in 5 fractions). Among these, 24 quality assurance (QA) plans were evaluated using homogeneous cylindrical phantoms and ionization chambers. Dose-volume histogram (DVH) was calculated, and gamma analysis (3%/1 mm, 10% threshold) was performed. IDCS aligned with measured data, with OPF and PDD/OCR errors within 3% and 4%, respectively, except for small-field underestimations in the build-up region. For QA plans, TPS overestimated the measured dose (RT: 0.5% ± 2.6%, p = 0.58, MC: 1.7% ± 3.1%, p = 0.07), while IDCS underestimated it (- 1.3% ± 2.3%, p = 0.07). Gamma passing rates were 98.9% ± 1.5% (TPS-RT vs. IDCS) and 99.9% ± 0.3% (TPS-MC vs. IDCS). DVH metrics (planning target volume [PTV]: D
Indexed as
Identifiers
41102580What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.